Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03424980 : A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors
Phase
AgesMin: N/A Max: N/A
Eligibility
Inclusion Criteria:

- The patients were treated with lung cancer and were enrolled from Jan 2013 to Jun 2017

- The patients with advanced (Clinical stage: Phase IV) non-small cell lung cancer who
have complete core health medical records (HMRs);

- The patients who are observed with brain metastases diagnosed by imaging methods;

- The patients who have complete clinical data for diagnosis time of brain metastases,
and overall survival/effectiveness;

- The patients who are administered with tyrosine kinase inhibitors only or combination
therapies of tyrosine kinase inhibitors;

Exclusion Criteria:

No exclusion criteria are included in the study given that the study is designed as
non-interventional and all the treatments followed real-world clinical practice and
experiences of clinical physicians.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT03424980      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740